Status and phase
Conditions
Treatments
About
This is a Phase II, multicenter, open-label, randomized, standard of care (SOC) controlled, multiple ascending dose study to assess the safety and tolerability of IV Brincidofovir (BCV) in subjects with BKV infection after kidney transplantation. The study will be conducted at multiple study sites in several countries including Australia and Japan. Subjects who meet eligibility criteria will be enrolled in the study and will be randomized and assigned to BCV or SOC (defined as use of the same immunosuppressant administered during prescreening) before receipt of the first dose of study drug in both the Dose Escalation Phase and the Expansion Phase.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
(Note: Immunosuppressant reduction needs to be continued during the screening period).
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
36 participants in 3 patient groups
Loading...
Central trial contact
Yuji Hoshino
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal